PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -167.53% | -42.92% | 107.82% | 64.67% | -0.64% |
| Total Depreciation and Amortization | 134.62% | 222.56% | 684.86% | 2,700.61% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 235.36% | 175.48% | -154.93% | 3,176.67% | -- |
| Change in Net Operating Assets | -291.20% | 204.60% | 919.30% | -95.57% | 756.66% |
| Cash from Operations | -289.80% | 1,975.50% | 222.46% | 152.93% | 162.51% |
| Capital Expenditure | -315.19% | -1,014.00% | -736.00% | -30,898.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 24.33% | 24.33% | -1,178.71% | -22,071.67% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 17.52% | 17.85% | -1,177.20% | -27,012.87% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -140.05% | -201.59% | -280.89% | -1,161.44% | -- |
| Issuance of Common Stock | -22.02% | -22.02% | -88.50% | -61.54% | 352,351.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -10.08% | -11.38% | -89.38% | -62.34% | 344,658.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.33% | 15.59% | -188.08% | -161.93% | 1,827.52% |